Literature DB >> 15096482

Vaccination with an immunodominant peptide of bovine type II collagen induces an anti-TCR response, and modulates the onset and severity of collagen-induced arthritis.

Aki Honda1, Akio Ametani, Takashi Matsumoto, Amane Iwaya, Hiroshi Kano, Satoshi Hachimura, Kensuke Ohkawa, Shucihi Kaminogawa, Koji Suzuki, Eli E Sercarz, Vipin Kumar.   

Abstract

T cell responses directed toward TCR-derived peptides have been shown to be an important regulatory mechanism of protection against autoimmunity. Here, we show that a naturally induced TCR-directed immune response can delay the onset of collagen-induced arthritis (CIA), an animal model of autoimmune rheumatoid arthritis in humans. DBA/1 mice were pretreated with an immunodominant peptide, p245-270, from bovine type II collagen (bCII) and were subsequently immunized with whole bCII for the induction of arthritis. The results showed that preactivation of p245-270-reactive cells delayed the onset and reduced the severity of CIA, compared with animals in the control group. Interestingly, the serum antibody response to bCII and the bCII-specific cytokine were not affected under these conditions. This result indicates that the observed protection was neither directly due to a lower antibody response nor due to the immune deviation of the anti-bCII T cell response. Furthermore, immunization with p245-270, but not bCII, induced a strong response to the B5 peptide, an immunodominant region of the TCR V(beta)8.2 (amino acids 76-101) that binds very strongly to I-A(q). These data suggest that at a critical phase in the loss of self-tolerance, an effective anti-TCR response, induced naturally, can regulate the pathogenic autoimmune response and thus may provide protection against autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15096482     DOI: 10.1093/intimm/dxh075

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  7 in total

1.  Tolerance induction using lentiviral gene delivery delays onset and severity of collagen II arthritis.

Authors:  Inger Gjertsson; Karen L Laurie; James Devitt; Steven J Howe; Adrian J Thrasher; Rikard Holmdahl; Kenth Gustafsson
Journal:  Mol Ther       Date:  2009-01-27       Impact factor: 11.454

2.  Vaccination without autoantigen protects against collagen II-induced arthritis via immune deviation and regulatory T cells.

Authors:  Irina Kochetkova; Theresa Trunkle; Gayle Callis; David W Pascual
Journal:  J Immunol       Date:  2008-08-15       Impact factor: 5.422

3.  LEAPS therapeutic vaccines as antigen specific suppressors of inflammation in infectious and autoimmune diseases.

Authors:  Daniel H Zimmerman; Harold Steiner; Roy Carmabula; Eyal Talor; Ken S Rosenthal
Journal:  J Vaccines Vaccin       Date:  2012-09-20

4.  Immune responses induced by T-cell vaccination in patients with rheumatoid arthritis.

Authors:  Irina Ivanova; Galina Seledtsova; Sergey Mamaev; Alexey Shishkov; Viktor Seledtsov
Journal:  Hum Vaccin Immunother       Date:  2014-03-14       Impact factor: 3.452

Review 5.  Peptide-Based Vaccination Therapy for Rheumatic Diseases.

Authors:  Bin Wang; Shiju Chen; Qing Zheng; Yuan Liu; Guixiu Shi
Journal:  J Immunol Res       Date:  2020-03-18       Impact factor: 4.818

6.  A fructosylated peptide derived from a collagen II T cell epitope for long-term treatment of arthritis (FIA-CIA) in mice.

Authors:  Clara Wenhart; Hans-Peter Holthoff; Andreas Reimann; Zhongmin Li; Julia Faßbender; Martin Ungerer
Journal:  Sci Rep       Date:  2021-08-30       Impact factor: 4.379

7.  Antigen-specific gene therapy after immunisation reduces the severity of collagen-induced arthritis.

Authors:  Tove Eneljung; Sara Tengvall; Pernilla Jirholt; Louise Henningsson; Rikard Holmdahl; Kenth Gustafsson; Inger Gjertsson
Journal:  Clin Dev Immunol       Date:  2013-11-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.